Gradient

News

Cure CMT Golf Challenge at Merit Club, in Libertyville, IL, Monday, June 29, 2026

Join us for the Cure CMT Golf Challenge at Merit Club, in Libertyville, IL, Monday, June 29, 2026. Cure CMT is making a difference by funding leg braces and surgeries for CMT patients, dramatically improving their mobility and quality of life. Cure CMT is also investing in the promising technologies BIO-Pharma has to offer to accelerate the path toward a first treatment/cure! Merit Club 1500 Merit Club Lane Libertyville, IL 60064 10:30 am arrival time Register now

Learn more

ReviR Therapeutics Receives Strategic Investment from CureCMT

ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT An isogenic iPSC and AI-enabled disease modeling platform spanning multiple genetically defined CMT subtypes will be established to support patient stratification, accelerate RTX-117 development, and create a shared foundation for next-generation therapies BRISBANE, Calif., April 21, 2026 /PRNewswire/ -- ReviR Therapeutics today announced a strategic investment from CureCMT to support the launch of a precision medicine platform for Charcot-Marie-Tooth disease (CMT). The platform will…

Learn more

ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study

ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat rare and genetic diseases, today announced a pivotal clinical and dual regulatory milestone: the first participant has been dosed…

Learn more

Cure CMT Announces Strategic Investment in EverTree Bio to Accelerate CMT1A Therapeutic Development

Cure CMT, a patient-driven venture philanthropy organization dedicated to accelerating treatments for Charcot–Marie–Tooth (CMT) disease, today announced a strategic investment in EverTree Bio to support the advancement of the company’s therapeutic program for Charcot–Marie–Tooth disease type 1A (CMT1A). The investment reflects Cure CMT’s mission to catalyze high-impact, translational programs that can meaningfully improve outcomes for patients and families. The investment was evaluated through Cure CMT’s CURES Team, the organization’s scientific and diligence committee. The review included scientific rationale, development feasibility,…

Learn more